Advances in Pharmacoepidemiology and Drug Safety

Advances in Pharmacoepidemiology and Drug Safety
Open Access

ISSN: 2167-1052

+44 1202068036


A Survey of Clarithromycin Monotherapy for Patients with MAC Lung Disease in Japan

Tomohide Iwao*


The number of patients with nontuberculous mycobacteriosis (NTM) has increased exponentially in recent years. In Japan, approximately 88.8% of patients with NTM suffer from Mycobacterium avium-intracellulare complex (MAC) Lung Disease. Incidence of MAC Lung Disease is increasing owing to a rapid increase in nontuberculous
mycobacterial infections. Although basic treatment for MAC Lung Disease is chemotherapy, clarithromycin monotherapy is contraindicated by specialists owing to its high potential to induce drug-resistant bacterial strains in patients with MAC Lung Disease. However, it is unclear how much such treatment cases exist in clinical practical. This is because no long-term investigation has been carried out.

Materials and Methods

This study investigated treatment with these medications from 2005 to 2017, by studying 1107 patients with MAC Lung Disease based on data in patient insurance claims.


Results showed that approximately 10.3% (114 cases) were prescribed long-term CAM monotherapy
for three months.


Generally, administration of antibiotics over a long period of time is potentially detrimental to some patients. Better awareness of the types of treatments and their potential negative effects will be beneficial to clinical practitioners. In the immediate future, it seems to be effective to develop an educational system on single agent
administration of antimicrobial agents.

Published Date: 2019-03-07; Received Date: 2019-01-31